bioRxiv Science⌕ Search

Biology subjects

Young, L. S.

Publications and source records attributed to Young, L. S..

3 recordsLinked to original sources

Star-Motifs: Revealing Single-Cell Spatiotypes from Routine Histology Using Star-Convex Neighborhoods

The tumor microenvironment (TME) is a dynamic interplay among cancer, immune, and stromal cells that profoundly influences tumor growth, progression, and treatment response. Although recent spatial transcriptomics and multiplex imaging technologies offer fine-grained insights into the TME, their high cost and lengthy turnaround times limit routine clinical use. In contrast, whole slide images (WSIs) of Hematoxylin and eosin (H&E)-stained are readily available for most patients and provide valuable information about tumor biology. Here, we present a method that explicitly models each cells local neighborhood to identify recurrent spatial patterns, which we call "Star-Motifs." We first encode the local microenvironment of each cell using a "Star-Environment" representation that captures distances and angles to multiple surrounding cell types. We then perform unsupervised clustering of these descriptors to discover distinct Star-Motifs. We validated our method on 1.8 billion cells across 3,105 diagnostic slides from The Cancer Genome Atlas, spanning five distinct cell types: neoplastic, inflammatory, stromal, necrotic, and non-neoplastic. Our method uncovered a diverse range of Star-Motifs, from densely packed tumor clusters to tumor cells surrounded by immune cells (tumor-infiltrating lymphocytes). At the patient level, the relative abundances of these Star-Motifs correlate with patient survival outcomes, immune subtypes, and molecular alterations, offering interpretable, clinically relevant insights. Moreover, classical machine learning models trained on these abundances match or surpass deep learning approaches in predicting overall survival and immune-related biomarkers while remaining interpretable. By capturing higher-order spatial arrangements from routinely available histology slides, Star-Motifs provides a scalable, transparent platform for TME profiling, biomarker discovery, and personalized risk assessment in oncology.

cancer biology↗

The Ubiquitin-Proteasome System is an Important Driver of EBV-Associated Nasopharyngeal Carcinoma Progression: A Meta-Analysis of Transcriptomics Data

BackgroundEpstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is characterized by extensive immune infiltration, yet immune evasion remains a hallmark of the disease. In this study, we aimed to leverage publicly available datasets to identify EBV-host gene interactions and re-map their expression at single-cell resolution. MethodsWe conducted a meta-analysis of transcriptomic datasets to identify differentially expressed genes in NPC, mapped these genes to EBV-host interaction data, and constructed a network. Network clustering and pathway enrichment were performed, and single-cell RNA sequencing datasets were used to map these genes at cellular resolution. We analysed differences in cell cycle, immune signaling, cell-cell interactions, and assessed prognostic associations of a 12-gene UPS signature using the GEPIA2 platform. ResultsWe identified 85 EBV-interacting DEGs, most regulated by lytic-phase proteins. MCODE clustering highlighted genes related to the ubiquitin-proteasome system (UPS). Single-cell analyses confirmed elevated UPS-related gene expression in NPC compared to EBV-negative oropharyngeal cancer. UPS-High cells exhibited lower proliferative activity, enriched stemness signaling, and reduced antigen presentation and immune activation, whereas UPS-Low cells showed marked upregulation of growth-promoting pathways. Survival analysis revealed that high UPS expression was associated with poorer outcomes in both pan-cancer and head and neck squamous cell carcinoma datasets. The proportion of UPS-High cells varied widely across patients. ConclusionUPS activity, influenced by EBV lytic proteins, is linked to immune evasion, stemness, proliferation, and adverse prognosis. These findings support UPS as a potential biomarker and therapeutic target in EBV-associated NPC, warranting NPC-specific validation and functional studies. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=129 SRC="FIGDIR/small/673297v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@14032bborg.highwire.dtl.DTLVardef@1c2b995org.highwire.dtl.DTLVardef@126185eorg.highwire.dtl.DTLVardef@9c5f6_HPS_FORMAT_FIGEXP M_FIG C_FIG EBV-driven ubiquitin-proteasome dysregulation in nasopharyngeal carcinoma revealed by bulk and single-cell transcriptomics, linked to immune evasion and poor survival.

cancer biology↗

A cell-based, spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants

The engagement of the SARS-CoV-2 spike protein with ACE2 is a critical step for viral entry to human cells and accordingly blocking this interaction is a major determinant of the efficacy of monoclonal antibody therapeutics and vaccine-elicited serum antibodies. The emergence of SARS-CoV-2 variants necessitates the development of adaptable assays that can be applied to assess the effectiveness of therapeutics. Through testing of a range of recombinant spike proteins, we have developed a cell based, ACE2/spike protein binding assay that characterises monoclonal anti-spike protein antibodies and neutralising antibodies in donor serum. The assay uses high-content imaging to quantify cell bound spike protein fluorescence. Using spike proteins from the original Wuhan SARS-CoV-2 virus, as well as the delta and omicron variants, we identify differential blocking activity of three monoclonal antibodies directed against the spike receptor binding domain. Importantly, biological activity in the spike binding assay translated to efficacy in a SARS-CoV-2 infection assay. Hence, the spike binding assay has utility to monitor anti-spike antibodies against the major known SARS-CoV-2 variants and is readily adaptable to quantify impact of antibodies against new and emerging SARS-CoV-2 variants.

cell biology↗